The 60-second version of Astonea Labs Limited — what it does, how it earns, and who it competes with, before any of the numbers below.
Nothing stands out as clearly deteriorating on the years of data available.
| Metric | FY23 | FY24 | FY25 | FY26 | 3Y CAGR |
|---|---|---|---|---|---|
| Revenue | ₹66 Cr | ₹79 Cr | ₹97 Cr | ₹148 Cr | +30.7% |
| EBITDA | ₹7 Cr | ₹12 Cr | ₹15 Cr | ₹14 Cr | +25.2% |
| EBITDA Margin | 10.7% | 15.1% | 15.6% | 9.5% | — |
| PAT (Net Profit) | ₹1 Cr | ₹4 Cr | ₹5 Cr | ₹5 Cr | +89.3% |
| EPS | ₹0.63 | ₹3.87 | ₹5.09 | — | — |
| ROE | 8.2% | 34.0% | 29.1% | 7.9% | — |
| ROCE | 12.0% | 25.1% | 27.5% | 11.4% | — |
| Total Debt | ₹36 Cr | ₹42 Cr | ₹53 Cr | ₹43 Cr | +6.1% |
| Free Cash Flow | -₹4 Cr | ₹0 Cr | -₹2 Cr | -₹28 Cr | — |
| Company | P/E | ROE |
|---|---|---|
| SUN PHARMACEUTICAL IND L | 34.9x | 14.5% |
| DR. REDDY S LABORATORIES | 31.0x | 8.8% |
| CIPLA LTD | 31.8x | 9.8% |
| DIVI S LABORATORIES LTD | 83.0x | 17.5% |
A reasonable business at a reasonable price. Nothing here is alarming and nothing is compelling, which usually means the decision rests on things this data cannot see — the industry's direction, management's intent, and what else is available to you.